HIPOVA-01: Cytoreductive Surgery and HIPEC in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial Cancer
Study Details
Study Description
Brief Summary
With 4,600 new cases in France in 2012, ovarian cancer is the seventh most common cancer in women and the fourth cause of mortality by cancer. Despite a high response rate to initial treatment, most patients will relapse within 2 years. No standard treatment has yet been established for patients with recurrent ovarian cancer.
Most patients with such recurrences are currently treated with new combinations of systemic chemotherapy. A repeated laparotomy with complete cytoreduction is also an option that several authors have used to obtain median survival rates of more than 30 months.
Twenty five percent of patients experiencing relapse present with platinum-resistant recurrence, occurring less than 6 months after chemotherapy completion. Recently, Pujade et al. showed that adding bevacizumab to chemotherapy significantly improves progression-free survival (PFS) in this subgroup of patients with poor prognoses (16.6 months versus 13.3 months in women treated with chemotherapy alone). Three case control studies have compared systemic chemotherapy and CRS (Cytoreduction Surgery) alone versus CRS plus HIPEC in patients with recurrent disease. They showed significantly improved results with the addition of HIPEC. In the French registry that included 474 patients with recurrence and peritoneal carcinomatosis, the median PFS was 13.8 months for platinum-resistant patients and 13 months for platinum-sensitive patients. Our hypothesis is that surgery would reduce the tumor burden and consequently the number of platinum-resistant tumor clones and that HIPEC would control the microscopic residual disease by increasing the tumor cell cytotoxicity.
We assume that adding a locoregional treatment to an "Aurelia-like" systemic treatment would improve the PFS. We aim to assess the benefit of adding surgery and HIPEC to the treatment of first or second platinum-resistant recurrence compared to chemotherapy + bevacizumab.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Cytoreductive surgery combined with HIPEC All patients will start with three cycles of CT-BEV 15 mg/kg, and will then be randomly. Then one cycle of monochemotherapy without bevacizumab is administered and followed by an interval CRS and HIPEC with postoperative chemotherapy and bevacizumab (CT-BEV - 15 mg/kg once every 3 weeks) until disease progression |
Procedure: Cytoreductive surgery combined with HIPEC
Cytoreductive surgery combined with HIPEC (Cisplatin 70 mg/m2).
|
| Active Comparator: Aurelia arm Chemotherapy and bevacizumab (CT-BEV) once every 3 weeks from enrollment until disease progression |
Drug: Chemotherapy and bevacizumab (CT-BEV)
Chemotherapy and bevacizumab (CT-BEV) 15 mg/kg once every 3 weeks from enrollment until disease progression (RECIST 1.1)
|
Outcome Measures
Primary Outcome Measures
- Progression free survival [Change from baseline to 36 months]
Progression will be based on RECIST V1.1 criteria performed on thoraco-abdominopelvic tomodensitometry (TDM ) assessed every 3 months. There is a follow-up period of 36 months.
Secondary Outcome Measures
- Overall survival [From the randomization to the death or 36 months end of follow-up]
There is a follow-up period of 36 months.
- Potential treatment-related mortality [During the first 60 postoperative days]
Reported only in the experimental arm (cytoreductive surgery + HIPEC)
- Potential treatment-related morbidity [During the first 60 postoperative days]
Adverse events (AE) during the follow-up period: safety and tolerability will be assessed in terms of AEs, deaths, laboratory data, and vital signs. AEs will be described using MedDRA terms (version 18.0) and graded according to Common Terminology Criteria for Adverse Events (CTCAE version 5.0). These will be collected for all randomized patients.
- Quality of life assessment [Baseline to 36 months end of follow-up]
Quality of Life will be assessed using the Functional Assessment of Cancer Therapy-Ovarian (FACT-O) for all randomized patients.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Histologically confirmed platinum-resistant Epithelial Ovarian Carcinoma (EOC)(clinical recurrence or persistence within 6 months of last treatment);
-
White blood cells >3,500/mm3, neutrophils ≥1,500/mm3, platelets ≥100,000/mm3;
-
Good renal function: serum creatinine values <1.5 mg/dl, creatinine clearance >60 ml/min;
-
Performance Status ≤2, Karnofsky Index ≥70%;
-
Serum bilirubin ≤1.5 x Upper limit of normal (UNL) 2 mg/dl;
-
Prior ovarian surgery before starting study treatment;
-
Covered by a Healthcare System, where applicable, and/or in compliance with the recommendations of the national laws in force relating to biomedical research;
-
Signed written informed consent obtained prior to any study-specific screening procedures.
Exclusion Criteria:
-
Platinum-refractory EOC (i.e progression under platinum containing chemotherapy);
-
Any prior malignancy not considered in complete remission for at least 2 years;
-
Pregnancy or breastfeeding;
-
Untreated central nervous system disease or symptomatic central nervous system metastasis, history or evidence of thrombotic or hemorrhagic disorders within 6 months before first study treatment;
-
Uncontrolled hypertension or active clinically significant cardiovascular disease;
-
Females of childbearing age not using medically accepted contraceptive measures, as judged by the investigator;
-
Contraindication to any drug contained in the chemotherapy regimen;
-
Known contraindication to cisplatin
-
Medical, geographical, sociological, psychological or legal conditions that would prevent the patient from completing the study or signing the informed consent;
-
Any significant disease which, in the investigator's opinion, excludes the patient from the study;
-
Under any administrative or legal supervision.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Centre Hospitalier Universitaire Jean Minjoz | Besançon | France | 25030 | |
| 2 | Centre Hospitalier Universitaire Jean Minjoz | Besançon | France | 25030 | |
| 3 | Centre Oscar Lambret | Lille | France | 59000 | |
| 4 | CHRU Claude Huriez | Lille | France | 59067 | |
| 5 | Centre Léon Bérard | Lyon | France | 69008 | |
| 6 | Centre Léon Bérard | Lyon | France | 69008 | |
| 7 | Institut du Cancer de Montpellier | Montpellier | France | 34298 | |
| 8 | Institut du Cancer de Montpellier | Montpellier | France | 34298 | |
| 9 | Centre Hospitalier Universitaire L'Archet II | Nice | France | 06200 | |
| 10 | Centre Hospitalier Universitaire L'Archet II | Nice | France | 06200 | |
| 11 | Centre Hospitalier Universitaire L'Archet II | Nice | France | 06200 | |
| 12 | Hôpital Européen Georges Pompidou - APHP | Paris | France | 75015 | |
| 13 | Centre Hospitalier Lyon Sud | Pierre-benite | France | 69495 | |
| 14 | Centre Hospitalier Lyon Sud | Pierre-Bénite | France | ||
| 15 | Centre Hospitalier Universitaire de Poitiers | Poitiers | France | 86021 | |
| 16 | Centre Hospitalier Universitaire de St Etienne | Saint-priest-en-jarez | France | 42270 | |
| 17 | Centre Hospitalier Universitaire de St Etienne | Saint-Priest-en-Jarez | France | 42270 | |
| 18 | Institut de Cancérologie de la Loire | Saint-Priest-en-Jarez | France | 42270 | |
| 19 | Centre Hospitalier Universitaire Hautepierre | Strasbourg | France | 67200 | |
| 20 | Centre Hospitalier Universitaire Hautepierre | Strasbourg | France | 67200 | |
| 21 | Centre Hospitalier Universitaire Hautepierre | Strasbourg | France | 67200 | |
| 22 | Institut de Cancérologie de Lorraine - Alexis Vautrin | Vandœuvre-lès-Nancy | France | 54519 |
Sponsors and Collaborators
- Hospices Civils de Lyon
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 69HCL17_0342